JP4611632B2 - メトロニダゾールを含む水性組成物 - Google Patents
メトロニダゾールを含む水性組成物 Download PDFInfo
- Publication number
- JP4611632B2 JP4611632B2 JP2003557494A JP2003557494A JP4611632B2 JP 4611632 B2 JP4611632 B2 JP 4611632B2 JP 2003557494 A JP2003557494 A JP 2003557494A JP 2003557494 A JP2003557494 A JP 2003557494A JP 4611632 B2 JP4611632 B2 JP 4611632B2
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- metronidazole
- cyclodextrin
- aqueous solution
- niacin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2301/02—Cellulose; Modified cellulose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Medical Informatics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
メトロニダゾール、1−(2−ヒドロキシエチル)−2−メチル−5−ニトロイミダゾールは、長い間、様々な疾患を処置するのに有効な薬剤として知られており、特に様々な原虫症の処置で良く知られている。局所療法としては、メトロニダゾールはまた、酒さ、細菌性潰瘍、及び口周囲皮膚炎などの、様々な皮膚疾患を処置するのに有用であることが示された。Borgman、米国特許第4,837,378号を参照。メトロニダゾールは、皮膚疾患を処置するのに局所的に使用されると、抗炎症活性を有することが分かっている。Czernielewskiら、米国特許第5,849,776号を参照。メトロニダゾールはまた、細菌性膣症の処置のための膣内の治療剤として使用される可能性がある。Borgman、米国特許第5,536,743号を参照。
驚くべきことに、シクロデキストリン及びニコチン酸アミドまたはナイアシン等の、第2の溶解促進剤との組み合わせが、メトロニダゾール等の両親媒性または親油性化合物(chemical compound)の水溶性に相乗効果を有することが発見された。第2の溶解促進剤はニコチン酸アミドまたはナイアシン以外であってもよい。シクロデキストリン及び第2の溶解促進剤の組み合わせによって提供される相乗効果によって、第2の溶解促進剤を使用しない場合に化合物の所望のレベルの溶解性を得るのに必要である濃度より低い濃度でのシクロデキストリンの使用が可能である。シクロデキストリンは高価であり、水溶性が限られており、完全に毒性がないわけではないため、本発明は、薬剤調製物の配合及び調製のコストをかなり下げる、さらにはBCD等のシクロデキストリンの可溶化能を向上し、さらにシクロデキストリンの使用量は最小限にしたままで所望の濃度の薬理化合物を得るための重要な方法を提供するものである。
図1は、本発明のキットの好ましい実施態様の代表的な図を示す。
予想できなかったことに、0.75% w/wを超えるおよび約1%以上でさえあるメトロニダゾール(MTZ)の安定した水溶液が、一方の溶解促進剤がBCD等のシクロデキストリンであり、第2の溶解促進剤がシクロデキストリン以外である、溶解促進剤の組み合わせを用いることによって得られることを発見した。適当な第2の促進剤の例としては、ナイアシン及びニコチン酸アミドが挙げられる。
下記実施例のすべての溶液は、一般式として列挙される成分または表1に示されるゲルベヒクルを含む。
メトロニダゾールの様々な濃度を、0.5% BCDを含む実施例1のゲルベヒクルを用いて調製した。メトロニダゾール(MTZ)/BCD溶液を5℃で1週間、維持した。結果を表3に示す。
様々な濃度のニコチン酸アミドを用いた同様の研究から、1.0%メトロニダゾールの安定した水性ゲル溶液を得るのに必要なニコチン酸アミドの濃度は約3%であることが示された。表1の様々なゲル溶液を、1.0%メトロニダゾールの濃度を用い、0.5%または1.0% BCDを含み、ニコチン酸アミドの濃度を変えて、調製した。ゲルを、5℃で1週間、維持して、沈殿物または結晶の形成を観察した。結果を表4に示す。
表1の様々なゲル溶液を、1.0%メトロニダゾールの濃度及び様々なナイアシン濃度を用いて調製した。pHを、トロラミンで5.0±0.15に調節した。溶液を5℃で1週間、維持して、沈殿物または結晶の形成の形跡を観察した。結果を表5に示す。
1%メトロニダゾール、0.5%ナイアシンを有し、pHを5.0±0.15に調節し、さらにBCDの濃度を変えた、表1による様々な溶液。溶液を5℃で1週間、維持して、結晶または沈殿物の形成を観察した。結果を表6に示す。
Claims (30)
- メトロニダゾール、β−シクロデキストリン(BCD)である第1の溶解促進剤、及びナイアシンまたはニコチン酸アミドである第2の溶解促進剤を含み、該β−シクロデキストリンの濃度が0.5〜1.0% w/wであり、及び該ナイアシンの濃度が0.5〜2.0% w/wでありまたは該ニコチン酸アミドの濃度が1.0〜3.0% w/wであり、水溶液におけるメトロニダゾールの濃度が1.0〜1.25% w/wである、少なくとも7日間、5℃の冷蔵温度で貯蔵される際に、溶液に結晶または沈殿物を生じない水溶液。
- 該第2の溶解促進剤はニコチン酸アミドである、請求項1に記載の水溶液。
- 該第2の溶解促進剤はナイアシンである、請求項1に記載の水溶液。
- ナイアシンの濃度が1.0〜2.0% w/wである、請求項1または3に記載の水溶液。
- ゲル状である、請求項1〜4のいずれか1項に記載の水溶液。
- メトロニダゾール、β−シクロデキストリン(BCD)、及びナイアシンまたはニコチン酸アミドを水性液体中で混合することを有し、この際、水性液体中で混合されるβ−シクロデキストリンの量は、水溶液中のβ−シクロデキストリンの濃度を0.5〜1.0% w/wにするのに十分な量であり、水性液体中で混合されるナイアシンの量は、水溶液中のナイアシンの濃度を0.5〜2.0% w/wにするのに十分な量である、または水性液体中で混合されるニコチン酸アミドの量は、水溶液中のニコチン酸アミドの濃度を1.0〜3.0% w/wにするのに十分な量である、5℃で1週間貯蔵しても溶液に結晶または沈殿物を生じない0.75% w/wを超えかつ1.25% w/w以下である濃度のメトロニダゾールの水溶液の製造方法。
- メトロニダゾールは、BCD及びナイアシンまたはニコチン酸アミドを水性液体中に溶解した後に水性液体に添加される、請求項6に記載の方法。
- メトロニダゾール、BCD、及びナイアシンまたはニコチン酸アミドを混合した後に、ゲル化剤を添加することをさらに有する、請求項6または7に記載の方法。
- ニコチン酸アミドを混合する、請求項6〜8のいずれか1項に記載の方法。
- ナイアシンを混合する、請求項6〜8のいずれか1項に記載の方法。
- 請求項6〜10のいずれか1項に記載の方法によって作製される水溶液。
- メトロニダゾール、β−シクロデキストリン(BCD)、及びナイアシンまたはニコチン酸アミドを水性液体中に混合することを有する水溶液中のメトロニダゾールの溶解性の向上方法。
- 水性液体中のβ−シクロデキストリンの濃度が0.5〜1.0% w/wであり、及び水性液体中のナイアシンの濃度が0.5〜2.0% w/wであるまたは水性液体中のニコチン酸アミドの濃度が1.0〜3.0% w/wである、請求項12に記載の方法。
- 該水溶液はゲル状である、請求項12または13に記載の方法。
- 水性液体中にニコチン酸アミドを混合することを有する、請求項12〜14のいずれか1項に記載の方法。
- 水性液体中にナイアシンを混合することを有する、請求項12〜14のいずれか1項に記載の方法。
- メトロニダゾールの溶解度が0.75〜1.25% w/wにまで増加する、請求項12〜16のいずれか1項に記載の方法。
- メトロニダゾールの溶解度が1.0〜1.25% w/wにまで増加する、請求項17に記載の方法。
- 水性液体中でナイアシンまたはニコチン酸アミドをβ−シクロデキストリンと混合することを有する、β−シクロデキストリンによる該水性液体におけるメトロニダゾールの溶解性の促進効果を向上する方法。
- 水性液体中のβ−シクロデキストリンの濃度が0.5〜1.0% w/wであり、及び水性液体中のナイアシンの濃度が0.5〜2.0% w/wであるまたは水性液体中のニコチン酸アミドの濃度が1.0〜3.0% w/wである、請求項19に記載の方法。
- ナイアシンを水性液体中でβ−シクロデキストリンと混合する、請求項19または20に記載の方法。
- ニコチン酸アミドを水性液体中でβ−シクロデキストリンと混合する、請求項19または20に記載の方法。
- メトロニダゾール、β−シクロデキストリン(BCD)、及びナイアシンまたはニコチン酸アミドを含む水溶液であって、該水溶液は、7日間、5℃で貯蔵した際に、結晶または沈殿物を生じない、水溶液。
- 水溶液におけるβ−シクロデキストリンの濃度が0.5〜1.0% w/wである、請求項23に記載の水溶液。
- 水溶液におけるβ−シクロデキストリンの濃度が1.0% w/wである、請求項23または24に記載の水溶液。
- 水性ゲルを含む水溶液である、請求項23〜25のいずれか1項に記載の水溶液。
- 容器および該容器内にメトロニダゾール、β−シクロデキストリン、及びナイアシンまたはニコチン酸アミドの水溶液を含み、該水溶液におけるメトロニダゾールの濃度が0.75% w/wより高くかつ1.25% w/w以下である、皮膚または粘膜疾患の局所処置のためのキット。
- β−シクロデキストリンの濃度が0.5〜1.0% w/wであり、及びナイアシンの濃度が0.5〜2.0% w/wであるまたはニコチン酸アミドの濃度が1.0〜3.0% w/wである、請求項27に記載のキット。
- メトロニダゾールの濃度が1〜1.25% w/wである、請求項27または28に記載のキット。
- 該水溶液はゲル状である、請求項27〜29のいずれか1項に記載のキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/033,835 US6881726B2 (en) | 2001-12-24 | 2001-12-24 | Aqueous compositions containing metronidazole |
PCT/US2002/036063 WO2003057135A2 (en) | 2001-12-24 | 2002-11-07 | Aqueous compositions containing metronidazole |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005532990A JP2005532990A (ja) | 2005-11-04 |
JP2005532990A5 JP2005532990A5 (ja) | 2006-01-05 |
JP4611632B2 true JP4611632B2 (ja) | 2011-01-12 |
Family
ID=21872727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003557494A Expired - Lifetime JP4611632B2 (ja) | 2001-12-24 | 2002-11-07 | メトロニダゾールを含む水性組成物 |
Country Status (20)
Country | Link |
---|---|
US (4) | US6881726B2 (ja) |
EP (3) | EP2241320A1 (ja) |
JP (1) | JP4611632B2 (ja) |
KR (1) | KR100718858B1 (ja) |
CN (1) | CN100411624C (ja) |
AR (1) | AR037755A1 (ja) |
AT (1) | ATE481105T1 (ja) |
AU (1) | AU2002340458B2 (ja) |
BR (1) | BRPI0215331B8 (ja) |
CA (1) | CA2470492C (ja) |
CY (1) | CY1111095T1 (ja) |
DE (1) | DE60237710D1 (ja) |
DK (1) | DK1467744T3 (ja) |
ES (1) | ES2352656T3 (ja) |
HK (1) | HK1071514A1 (ja) |
MX (1) | MXPA04006210A (ja) |
PT (1) | PT1467744E (ja) |
RU (2) | RU2284810C2 (ja) |
WO (1) | WO2003057135A2 (ja) |
ZA (1) | ZA200405059B (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6468989B1 (en) * | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
DE10306453A1 (de) * | 2003-02-17 | 2004-08-26 | Deutsche Telekom Ag | Administrator |
US7456207B2 (en) * | 2003-09-25 | 2008-11-25 | Teva Pharmaceuticals Usa, Inc. | Vaginal pharmaceutical compositions and methods for preparing them |
FR2866566A1 (fr) * | 2004-02-20 | 2005-08-26 | Galderma Res & Dev | Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee |
FR2887149B1 (fr) | 2005-06-17 | 2007-08-03 | Galderma Sa | Procede de solubilisation du metronidazole |
US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
ATE498027T1 (de) * | 2005-12-07 | 2011-02-15 | Univ Ramot | Wirkstoffabgebende verbundkörper |
KR101500020B1 (ko) * | 2007-03-12 | 2015-03-06 | 디에스엠 아이피 어셋츠 비.브이. | 미용 조성물 |
US20080287513A1 (en) * | 2007-05-14 | 2008-11-20 | Jerry Zhang | Topical compositions containing metronidazole |
US20080287514A1 (en) * | 2007-05-14 | 2008-11-20 | Jerry Zhang | Topical compositions containing metronidazole |
US20080312304A1 (en) * | 2007-06-13 | 2008-12-18 | Jerry Zhang | Topical compositions containing metronidazole |
ES2439497T3 (es) * | 2007-09-04 | 2014-01-23 | Meiji Seika Pharma Co., Ltd. | Preparación de una inyección, de una solución para inyección y de un kit de inyección |
AR061947A1 (es) * | 2008-01-08 | 2008-08-10 | Oscar Belluscio Daniel | Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina |
US7893097B2 (en) | 2008-02-02 | 2011-02-22 | Dow Pharmaceutical Sciences, Inc. | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
US20110091515A1 (en) * | 2008-06-12 | 2011-04-21 | Ramot At Tel-Aviv University Ltd. | Drug-eluting medical devices |
US8729108B2 (en) * | 2008-06-17 | 2014-05-20 | Christopher J Dannaker | Waterborne topical compositions for the delivery of active ingredients such as azelaic acid |
WO2010047831A1 (en) * | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
EP2201930A1 (en) | 2008-12-23 | 2010-06-30 | Intendis GmbH | Hydrogel composition for the treatment of dermatological disorders |
AU2010237599A1 (en) * | 2009-04-14 | 2011-12-08 | Medortus (Uk) Ltd | Gel compositions for administration of pharmaceutically active compounds |
CN105903028B (zh) * | 2010-12-31 | 2020-10-16 | 东塘实验室有限公司 | 含有环糊精的细胞水合组合物 |
US20120171184A1 (en) | 2010-12-31 | 2012-07-05 | Lajos Szente | Cellular hydration compositions |
BR112013016809A2 (pt) * | 2010-12-31 | 2016-09-27 | Eastpond Lab Ltd | composições de hidratação celular |
CA2825417A1 (en) | 2011-01-25 | 2012-08-02 | The Procter And Gamble Company | Liposome and personal care composition comprising thereof |
CA2840571C (en) | 2011-06-28 | 2020-03-24 | Medicis Pharmaceutical Corporation | High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
EP2952208A1 (en) * | 2014-06-04 | 2015-12-09 | Universidade de Santiago de Compostela | Hydroalcoholic system for nail treatment |
JP2015044850A (ja) * | 2014-11-07 | 2015-03-12 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
US9492374B2 (en) * | 2015-03-25 | 2016-11-15 | Jose Rafael Salinas Andrade | Composition and method for treatment of ulcers |
IL275339B2 (en) | 2017-12-15 | 2024-03-01 | Tarsus Pharmaceuticals Inc | Parasitic formulations containing isoxazoline and methods for treating blepharitis |
US11198831B2 (en) | 2019-01-31 | 2021-12-14 | Kvi Llc | Lubricant for a device |
CN111840632A (zh) * | 2019-04-25 | 2020-10-30 | 广东泰宝医疗科技股份有限公司 | 一种含止血微囊的液体敷料及其制备方法 |
US20230218657A1 (en) * | 2020-06-02 | 2023-07-13 | National University Of Singapore | Compositions, their uses in therapy and methods thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4032645A (en) * | 1975-06-19 | 1977-06-28 | G. D. Searle & Co. | Injectable metronidazole composition |
US4267169A (en) * | 1978-07-22 | 1981-05-12 | Toko Yakuhin Kogyo Kabushiki Kaisha | Novel preparation of clotrimazole |
GB8330969D0 (en) * | 1983-11-21 | 1983-12-29 | Wellcome Found | Promoting healing |
DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4837378A (en) * | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
ES2058503T5 (es) | 1988-03-29 | 1999-04-16 | Univ Florida | Formulaciones farmaceuticas para uso parenteral. |
US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
TW200402B (ja) | 1990-08-13 | 1993-02-21 | Senju Pharma Co | |
EP0605428B9 (en) | 1991-06-24 | 2003-01-02 | hCell Technology, Inc. | Hormone-secreting pancreatic cells maintained in long-term culture |
US5747341A (en) | 1991-06-24 | 1998-05-05 | Pacific Biomedical Research, Inc. | Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
EP0788305B1 (en) * | 1994-03-28 | 2004-11-03 | The Trustees of Columbia University in the City of New York | Composition for inactivating irritants in fluids |
FR2722098B1 (fr) * | 1994-07-06 | 1996-08-23 | Cird Galderma | Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine |
US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
KR20010023256A (ko) * | 1997-08-27 | 2001-03-26 | 헥살 아게 | 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물 |
US6017516A (en) * | 1997-10-31 | 2000-01-25 | Lekar Pharma Limited | Pharmaceutical dental formulation for topical application of metronidazole benzoate and chlorhexidine gluconate |
US6183766B1 (en) | 1999-02-12 | 2001-02-06 | The Procter & Gamble Company | Skin sanitizing compositions |
US6468989B1 (en) * | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
CN1116038C (zh) * | 2000-11-18 | 2003-07-30 | 雷文彬 | 一种治疗痤疮的外用药液 |
-
2001
- 2001-12-24 US US10/033,835 patent/US6881726B2/en not_active Expired - Lifetime
-
2002
- 2002-11-07 BR BRPI0215331A patent/BRPI0215331B8/pt not_active IP Right Cessation
- 2002-11-07 CA CA2470492A patent/CA2470492C/en not_active Expired - Fee Related
- 2002-11-07 AU AU2002340458A patent/AU2002340458B2/en not_active Expired
- 2002-11-07 EP EP10170977A patent/EP2241320A1/en not_active Withdrawn
- 2002-11-07 MX MXPA04006210A patent/MXPA04006210A/es active IP Right Grant
- 2002-11-07 KR KR1020047010051A patent/KR100718858B1/ko active IP Right Grant
- 2002-11-07 EP EP10170958A patent/EP2238980A1/en not_active Ceased
- 2002-11-07 WO PCT/US2002/036063 patent/WO2003057135A2/en active Application Filing
- 2002-11-07 RU RU2004122696/15A patent/RU2284810C2/ru active
- 2002-11-07 AT AT02778822T patent/ATE481105T1/de active
- 2002-11-07 PT PT02778822T patent/PT1467744E/pt unknown
- 2002-11-07 JP JP2003557494A patent/JP4611632B2/ja not_active Expired - Lifetime
- 2002-11-07 ES ES02778822T patent/ES2352656T3/es not_active Expired - Lifetime
- 2002-11-07 DK DK02778822.3T patent/DK1467744T3/da active
- 2002-11-07 CN CNB028283163A patent/CN100411624C/zh not_active Expired - Fee Related
- 2002-11-07 EP EP02778822A patent/EP1467744B1/en not_active Expired - Lifetime
- 2002-11-07 DE DE60237710T patent/DE60237710D1/de not_active Expired - Lifetime
- 2002-12-09 AR ARP020104758A patent/AR037755A1/es not_active Application Discontinuation
-
2004
- 2004-06-25 ZA ZA2004/05059A patent/ZA200405059B/en unknown
-
2005
- 2005-01-18 US US11/037,430 patent/US7348317B2/en not_active Expired - Lifetime
- 2005-04-04 HK HK05102782.3A patent/HK1071514A1/xx not_active IP Right Cessation
-
2006
- 2006-05-11 RU RU2006116252/15A patent/RU2413501C2/ru active
-
2008
- 2008-02-27 US US12/072,578 patent/US20080154030A1/en not_active Abandoned
-
2009
- 2009-10-27 US US12/589,680 patent/US20100048659A1/en not_active Abandoned
-
2010
- 2010-11-11 CY CY20101101017T patent/CY1111095T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4611632B2 (ja) | メトロニダゾールを含む水性組成物 | |
JP4130358B2 (ja) | メトロニダゾール含有ゲル組成物 | |
US20100105750A1 (en) | Stable metronidazole gel formulations | |
AU610495B2 (en) | Novel topical metronidazole formulations and therapeutic uses thereof | |
PT2204174E (pt) | Processo de solubilização do metronidazol com o auxílio de niacinamida e de dois glicóis, a solução assim obtida | |
US20080312304A1 (en) | Topical compositions containing metronidazole | |
EP2514409A1 (en) | Topical pharmaceutical compositions of nimesulide and methylsulfonylmethane | |
US20080287515A1 (en) | Topical compositions containing metronidazole | |
US20080287514A1 (en) | Topical compositions containing metronidazole | |
EP2505195A1 (en) | Topical pharmaceutical compositions of ketoprofen and methylsulfonylmethane | |
US20080287513A1 (en) | Topical compositions containing metronidazole | |
JP4485133B2 (ja) | 吸収促進組成物 | |
CA1297028C (en) | Topical metronidazole formulations and therapeutic uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050930 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090924 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100609 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100713 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100909 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101012 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101014 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131022 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4611632 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
EXPY | Cancellation because of completion of term | ||
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |